Company / Financials
Zentalis Pharmaceuticals, Inc. Financials
FY2024-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$0
FY2025
Net Income
-$292.2M
FY2025 · -23.4% YoY
Profit Margin
-
FY2025 · net income / revenue
ROE
-135.2%
FY2025 · return on equity
Total Assets
$289.0M
FY2025
Total Debt
-
FY2025
Equity
$216.2M
FY2025
ROA
-101.1%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -1.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$0Net Income HistoryProfit after all expenses and taxes-$292.2M-23.4% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$299.5M-31.8% YoYSG&A Expense HistorySelling, general, and administrative expenses$64.4M+18.0% YoYR&D Expense HistoryResearch and development spending$189.6M+9.8% YoYIncome Tax HistoryTotal income tax expense-$601.0K-28.1% YoYEPS (Basic) HistoryBasic earnings per share-$4.47+0.2% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$4.47+0.2% YoYShares Outstanding HistoryWeighted average diluted shares outstanding71.3M+0.7% YoYTotal Assets HistoryTotal value of all assets owned$289.0M-32.9% YoY